logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 20 of 28 Items
Showing 1 - 20 of 28 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

Improving equitable access for effective antibacterial: An ecosystem approach

Cohn J, Balasegaram M, Srinivasan H, Menghaney L, Mpundu M,  et al.
2025-03-01 • Clinical Microbiology and Infection
2025-03-01 • Clinical Microbiology and Infection

BACKGROUND

Antibiotics are indispensable to modern healthcare, yet their equitable access remains a pressing global challenge. Factors contributing to inequitie...

Journal Article
|
Letter

Different Liposomal Amphotericin B Formulations for Visceral Leishmaniasis

Dorlo TPC, Balasegaram M
2014-08-19 • Lancet Global Health
2014-08-19 • Lancet Global Health
Journal Article
|
Research

Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes

Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME,  et al.
2008-10-21 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2008-10-21 • Transactions of the Royal Society of Tropical Medicine and Hygiene
This paper describes the effectiveness of first-line regimens for stage 2 human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense infection in nine Médecins Sans Frontièr...
Journal Article
|
Research

Unresponsiveness to AmBisome in some Sudanese patients with kala-azar

Mueller M, Ritmeijer KKD, Balasegaram M, Koummuki Y, Santana MR,  et al.
2007-01-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2007-01-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
In Sudan, two treatments are currently registered for visceral leishmaniasis: sodium stibogluconate (SSG) as first line and liposomal amphotericin B (AmBisome) as second line. We present...
Protocol
|
Research Protocol

Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

Diro EGJ, Griensven JV, Woldegebreal T, Belew Z, Taye M,  et al.
2018-07-01
2018-07-01
2.1 OBJECTIVES
2.1.1 General objective:

To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients t...
Journal Article
|
Research

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G,  et al.
2014-01-02 • PLOS Neglected Tropical Diseases
2014-01-02 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as Kala-azar) is an ultimately fatal disease endemic in Bihar. A 2007 observational cohort study in Bihar of 251 patients with VL treated with 20 m...
Journal Article
|
Short Report

An open source pharma roadmap

Balasegaram M, Kolb P, McKew J, Menon J, Olliaro PL,  et al.
2017-04-18 • PLOS Medicine
2017-04-18 • PLOS Medicine
Journal Article
|
Research

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS,  et al.
2018-10-22 • PLOS Neglected Tropical Diseases
2018-10-22 • PLOS Neglected Tropical Diseases
BACKGROUND
In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...
Journal Article
|
Commentary

Research & development in the dark: what does it take to make one medicine? And what could it take?

Reid J, Balasegaram M
2016-06-29 • Clinical Microbiology and Infection
2016-06-29 • Clinical Microbiology and Infection
Earlier this year a series of advertisements appeared in London's Westminster tube stations asking viewers to consider a seemingly simple question, 'what does it take to make one medicin...
Journal Article
|
Commentary

Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries

Mendelson M, Rottingen JA, Gopinathan U, Hamer DH, Wertheim H,  et al.
2015-11-18 • Lancet
2015-11-18 • Lancet
Journal Article
|
Review

Liposomal amphotericin B as a treatment for human leishmaniasis

Balasegaram M, Ritmeijer KKD, Lima MA, Burza S, Ortiz Genovese G,  et al.
2012-11-20 • Expert Opinion on Emerging Drugs
2012-11-20 • Expert Opinion on Emerging Drugs
Journal Article
|
Research

Examples of tropical disease control in the humanitarian medical programmes of MSF and Merlin

Balasegaram M, Dejene S, Tinnemann P, Perkins S, Davidson RN
2006-04-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2006-04-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
Humanitarian medical programmes in the tropics have the opportunity to provide beacons of good practice. The use of modern drugs and diagnostics, a lack of bureaucracy, adequate budgets,...
Journal Article
|
Research

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Wassuna M, Njenga SN, Balasegaram M, Alexander N, Omollo R,  et al.
2016-09-14 • PLOS Neglected Tropical Diseases
2016-09-14 • PLOS Neglected Tropical Diseases
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBis...
Journal Article
|
Research

Melarsoprol Versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo

Balasegaram M, Harris SR, Checchi F, Ghorashian S, Hamel C,  et al.
2006-10-01 • Bulletin of the World Health Organization
2006-10-01 • Bulletin of the World Health Organization
OBJECTIVE
To compare the effectiveness of melarsoprol and eflornithine in treating late-stage Gambian trypanosomiasis in the Republic of the Congo.

METHODS
We analysed ...
Journal Article
|
Commentary

Is tiered pricing the way for vaccines?

Balasegaram M
2014-09-06 • Lancet
2014-09-06 • Lancet
Journal Article
|
Commentary

Developments in the treatment of visceral leishmaniasis

den Boer ML, Alvar J, Davidson RN, Ritmeijer KKD, Balasegaram M
2009-08-27 • Expert Opinion on Emerging Drugs
2009-08-27 • Expert Opinion on Emerging Drugs
BACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontine...
Journal Article
|
Research

A comparison of liposomal Amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan

Mueller M, Balasegaram M, Koummuki Y, Ritmeijer KKD, Santana MR,  et al.
2006-10-01 • Journal of Antimicrobial Chemotherapy
2006-10-01 • Journal of Antimicrobial Chemotherapy
OBJECTIVES: Little is known about the treatment of visceral leishmaniasis (VL) in pregnancy, especially in resource-poor settings. We present a series of pregnant women with VL treated w...
Journal Article
|
Letter

WHO: Steering plans for neglected diseases

Pecoul B, Balasegaram M
2014-04-27 • Nature
2014-04-27 • Nature
Journal Article
|
Research

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Hailu ADE, Musa AM, Wasunna M, Balasegaram M, Yifru S,  et al.
2010-10-26 • PLOS Neglected Tropical Diseases
2010-10-26 • PLOS Neglected Tropical Diseases
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is in...
Journal Article
|
Commentary

Diagnostic preparedness for infectious disease outbreaks

Perkins MD, Dye C, Balasegaram M, Brechot C, Mombouli JV,  et al.
2017-11-11 • Lancet
2017-11-11 • Lancet
Diagnostics are crucial in mitigating the effect of disease outbreaks. Because diagnostic development and validation are time consuming, they should be carried out in anticipation of epi...